The integration of diverse chemical tools like small-molecule
inhibitors,
activity-based probes (ABPs), and proteolysis targeting chimeras (PROTACs)
advances clinical drug discovery and facilitates the exploration of
various biological facets of targeted proteins. Here, we report the
development of such a chemical toolbox for the human Parkinson disease
protein 7 (PARK7/DJ-1) implicated in Parkinson’s disease and
cancers. By combining structure-guided design, miniaturized library
synthesis, and high-throughput screening, we identified two potent
compounds,
JYQ-164
and
JYQ-173
, inhibiting
PARK7
in
vitro
and in cells by covalently
and selectively targeting its critical residue, Cys106. Leveraging
JYQ-173
, we further developed a cell-permeable Bodipy probe,
JYQ-196
, for covalent labeling of PARK7 in living cells and
a first-in-class PARK7 degrader
JYQ-194
that selectively
induces its proteasomal degradation in human cells. Our study provides
a valuable toolbox to enhance the understanding of PARK7 biology in
cellular contexts and opens new opportunities for therapeutic interventions.